HIV-associated lymphoproliferative disorders: Single-center experience

Area of Science:

• Oncology
• Infectious Diseases
• Hematology

Background:

• Survival rates for human immunodeficiency virus (HIV)-positive individuals have improved due to advancements in lymphoma treatments and combination antiretroviral therapy (cART).
• Acquired immune deficiency syndrome (AIDS)-related lymphoma remains a significant clinical challenge, necessitating evaluation of current treatment strategies.

Purpose of the Study:

• To present demographic and clinical characteristics, prognosis, and survival data of AIDS-related lymphoma patients from a single-center experience.
• To assess the impact of combined anti-tumor treatments and cART on survival and response rates.

Main Methods:

• Retrospective review of 16 AIDS-related lymphoma patients treated between August 2010 and March 2022.
• Analysis of demographic data, clinical information, treatment details, and survival outcomes.
• Evaluation of treatment response in patients who completed initial therapy.

Main Results:

• The study included 15 males with a median age of 46.5 years, presenting with various lymphoma subtypes, predominantly at advanced stages.
• Eleven out of 16 patients (68.8%) achieved complete response and are still alive.
• Diagnosis of AIDS preceded lymphoma in 11 patients, with a median time from HIV infection to lymphoma diagnosis of 23.8 months.

Conclusions:

• Combination antiretroviral therapy (cART) administered concurrently with anti-tumor treatments demonstrates a favorable impact on survival and response rates in patients with AIDS-related lymphoma.
• These findings underscore the efficacy of integrated treatment approaches for this aggressive patient group.